NEW YORK. Aug. 24 – DNAPrint Genomics and scientific developer Pharsight have entered into a collaboration to empower DNAPrint’s pharmacogenomic product development, the company announced on Friday.

The terms of the contract, which is open-ended, call for Mountain View, Calif.-based Pharsight to provide DNAPrint with clinically phenotyped DNA specimens from patients who are taking medications known to elicit variable efficacy.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.